Beigene, Ltd. - Net Worth and Insider Trading
Beigene, Ltd. Net Worth
The estimated net worth of Beigene, Ltd. is at least $2 Million dollars as of 2024-11-29. Beigene, Ltd. is the 10% Owner of Leap Therapeutics Inc and owns about 734,844 shares of Leap Therapeutics Inc (LPTX) stock worth over $2 Million. Details can be seen in Beigene, Ltd.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Beigene, Ltd. has not made any transactions after 2021-09-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Beigene, Ltd.
Beigene, Ltd. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Beigene, Ltd. owns 1 companies in total, including Leap Therapeutics Inc (LPTX) .
Click here to see the complete history of Beigene, Ltd.’s form 4 insider trades.
Insider Ownership Summary of Beigene, Ltd.
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
LPTX | Leap Therapeutics Inc | 2021-09-24 | 10 percent owner |
Beigene, Ltd. Latest Holdings Summary
Beigene, Ltd. currently owns a total of 1 stock. Beigene, Ltd. owns 734,844 shares of Leap Therapeutics Inc (LPTX) as of September 24, 2021, with a value of $2 Million.
Latest Holdings of Beigene, Ltd.
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
LPTX | Leap Therapeutics Inc | 2021-09-24 | 734,844 | 2.92 | 2,145,744 |
Holding Weightings of Beigene, Ltd.
Beigene, Ltd. Form 4 Trading Tracker
According to the SEC Form 4 filings, Beigene, Ltd. has made a total of 1 transactions in Leap Therapeutics Inc (LPTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Leap Therapeutics Inc is the acquisition of 254,380 shares on September 24, 2021, which cost Beigene, Ltd. around $7 Million.
Insider Trading History of Beigene, Ltd.
- 1
Beigene, Ltd. Trading Performance
GuruFocus tracks the stock performance after each of Beigene, Ltd.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Beigene, Ltd. is -17.37%. GuruFocus also compares Beigene, Ltd.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Beigene, Ltd. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Beigene, Ltd.'s insider trading performs compared to the benchmark.
Performance of Beigene, Ltd.
Beigene, Ltd. Ownership Network
Beigene, Ltd. Owned Company Details
What does Leap Therapeutics Inc do?
Who are the key executives at Leap Therapeutics Inc?
Beigene, Ltd. is the 10 percent owner of Leap Therapeutics Inc. Other key executives at Leap Therapeutics Inc include Chief Scientific Officer Jason Baum , VP & Head of Reg Affairs/Qual Christine Granfield , and 10 percent owner Perceptive Life Sciences Master Fund Ltd .
Leap Therapeutics Inc (LPTX) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Leap Therapeutics Inc (LPTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Leap Therapeutics Inc (LPTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Leap Therapeutics Inc (LPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Leap Therapeutics Inc Insider Transactions
Beigene, Ltd. Mailing Address
Above is the net worth, insider trading, and ownership report for Beigene, Ltd.. You might contact Beigene, Ltd. via mailing address: C/o Mourant Governance Services (cayman), 94 Solaris Avenue, Camana Bay, Grand Cayman E9 Ky1-1108.